The HHS proposed reform would do Medicare patients more harm than good. Price controls may save the government money in the short term, but they would slow the rate of medical progress.
Democratic presidential frontrunner Joe Biden hopes to pay for his version of the Green New Deal by eliminating the subsidies and tax breaks given to the fossil fuel producing industry, and he’s not alone.
In an effort to improve the science used by regulatory agencies, the Trump administration has made, and is still making, adjustments in the way the Environmental Protection Agency (EPA) and other agencies approach climate change and make the predictions that drive climate policies. Not everyone is pleased, to put it mildly.
Some think Puerto Rico has been shortchanged. The numbers tell a more nuanced story.
The Iranian government is rattling sabers once again. In years past those tensions would have sent world oil markets into a panic. Not so this time around.
Sen. John Cornyn's legislation that attempts to address problems he sees with the patent protections afforded to American drug companies overreaches and would limit the ability of pharmaceutical firms to develop and improve medicines.
Most House Republicans have committed in one way or another to not raise taxes, but this seems to be a session characterized by commitments broken and principles betrayed.
It is difficult to see why those guilty of heinous crimes should retain their right to vote.
If lawmakers want to cut drug spending without leaving patients in the lurch, they’d be wise to foster more competition in the drug marketplace. Price controls
President Donald Trump’s trade war is a little over a year old, so it’s a good time to review its impact -- especially since he is rattling the steel-tariffs sword once again.